oncology
Lung Cancer

Precision medicine bugged by imprecise biopsy samples

The idealistic vision of precision oncology targeting tumours based on oncogene signatures has to overcome the current reality of unsatisfactory paraffin-fixed biopsy samples that can’t provide enough DNA for genome analysis, a conference has been told. Speaking at the Australasian Lung Cancer trials Group (ALTG) Annual Scientific Meeting in Sydney, Dr Katia Nones (PhD) a ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic